Its role Offtaker
Opella Healthcare is the consumer healthcare business of Sanofi S.A., operating under Opella legal entities in various markets. The company focuses on over-the-counter (OTC) medicines and self-care products spanning categories such as pain relief, digestive health, allergy, cough and cold, dermatology, and vitamins, minerals and supplements.
Opella Healthcare’s activities cover R&D, formulation, manufacturing and distribution of finished dosage forms, adhering to pharmaceutical quality systems and regulatory requirements (e.g., GMP). It works across the pharmaceuticals and chemicals supply chain for active pharmaceutical ingredients (APIs), excipients and packaging materials, supplying retail pharmacies, e-commerce and other consumer channels globally as part of Sanofi’s portfolio.
Also known as Opella Healthcare.
chemXplore tracks 1 project involving Opella, of which one is active.
1 more active project is in the record. See all 1 in chemXplore →
Continuous-flow, lower-footprint paracetamol process; 15,000 t/yr from end‑2026; backed by France 2030 with UPSA and Opella as partners.
The agreement reserves future volumes of plant-based polymer PEF, enhancing sustainable packaging innovation and supporting the development of high-performance solutions.
The new unit, supported by France Relance, will produce 10,000 tonnes of paracetamol annually by 2023, using innovative, eco-friendly processes to meet growing demand and enhance EU health sovereignty.
active all projects
What each is building and closing, and the pipelines and grids between them, on one map.
